Assurex Health | GenomeWeb

Assurex Health

The deal, which included $225 million in upfront payments and up to $185 million in milestones, gives Myriad entry into the neuroscience space.

Despite the historical adoption and reimbursement challenges for PGx testing firms, Myriad said it would try to achieve value-based pricing for Assurex's GeneSight test.

The deal will grant Myriad entry into the neuroscience space, and will allow it to use Assurex's existing sales force to market its own mental health tests. 

Investors included existing shareholders Sequoia Capital, Claremont Creek Ventures, Cincinnati Children’s Hospital Medical Center, and Mayo Clinic.

Luminex said its technology will enhance the processing speed and capacity of Assurex's tests.

The funds will go toward efforts to drive clinical adoption and further develop Assurex's GeneSight products.

 

AdvaMedDx, a division of the Advanced Medical Technology Association, announced the election of several new members to its board of directors.

People In The News

NEW YORK (GenomeWeb News) – AssureRx Health, a neuropsychiatric personalized medicine company, has formed a scientific advisory board, which will guide the company's R&D efforts on pharmacogenomic products.

AssureRx Health, a neuropsychiatric personalized medicine company, has formed a scientific advisory board, which will guide the company's R&D efforts on pharmacogenomic products.

People In The News

News
NEW YORK (GenomeWeb News) – Illumina’s board appointed Michel Bouchard Chief Accounting Officer, effective Jan. 1. He will continue to serve as vice president of finance for the firm, as well, a title he has held since joining Illumina in 2008.

Pages

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.